VanEck Associates
ARIA

VanEck Associates’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

VanEck Associates’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-534,249
Closed -$3.4M – 742
2014
Q2 		$3.4M Sell
534,249
-135,344
-20% -$931K 0.02% 291
2014
Q1 		$5.4M Buy
669,593
+170,389
+34% +$1.33M 0.03% 230
2013
Q4 		$3.4M Buy
499,204
+60,286
+14% +$325K 0.02% 270
2013
Q3 		$8.08M Buy
438,918
+12,914
+3% +$251K 0.04% 190
2013
Q2 		$7.45M Buy
+426,004
New +$7.55M 0.04% 183

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

VanEck Associates's ARIA Position: Q3 2014 in Review

VanEck Associates sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2014, closing a stake of 534,249 shares — an estimated $3.4M sold.

VanEck Associates first reported a position in ARIA in Q2 2013 and held it in 5 quarters. The position peaked at $8.08M in Q3 2013. 169 funds tracked by Wall St. Rank hold ARIA as of Q3 2014.

  • VanEck Associates reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • VanEck Associates sold 534,249 Ariad Pharmaceuticals Inc shares in Q3 2014, an estimated $3.4M.
  • VanEck Associates first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 5 quarters.
  • VanEck Associates's Ariad Pharmaceuticals Inc position peaked at $8.08M in Q3 2013.
  • 169 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2014.

Based on VanEck Associates's 13F filing for Q3 2014, filed 14 Nov 2014.